TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01208207
Drug: Part I - Placebo to etoricoxib 90 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
Study: NCT01208207
Drug: Part II- Placebo to etoricoxib 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
Study: NCT01208207
Drug: Part II - Placebo to etoricoxib 90 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
Study: NCT01208207
Drug: Part II- Placebo to naproxen 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to naproxen 500 mg orally twice daily for 20 weeks.
Study: NCT00548340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, PO daily for five weeks
Study: NCT03112603
Drug: Extracorporeal photopheresis (ECP)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
Study: NCT03112603
Drug: Low-dose methotrexate (MTX)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Study: NCT03417388
Drug: High dose potent statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.
Study: NCT01411124
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00156624
Drug: Balloon Angioplasty with or without drug administration
Normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04480359
Drug: Bawei Shenqi Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.1g, once a day, 3month, oral
Study: NCT04480359
Drug: Bawei Shenqi Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.1g, once a day, 3month, oral
Study: NCT00043979
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction - 750 mg/m\^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.~Transplant - 1200 mg/m\^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3.
Study: NCT00043979
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction - 10 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
Study: NCT04480359
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5mg, once a day, 3 month, oral
Study: NCT03367988
Drug: Opioid Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Anesthesia will be induced with rocuronium, propofol, intravenous opioids, and other medication(s)/agent(s) at a concentration range/dose(s) based on the clinical need of the subject.~Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with IV opioids, propofol and/or medication(s)/agent(s), including inhalation anesthetic agents, at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready.
Study: NCT03367988
Drug: Opioid-free Anesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Acetaminophen 1g will be given prior to induction. Anesthesia will be induced with rocuronium 1mg, propofol 3-6 mg/kg, and succinylcholine 1.5 mg/kg Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready.
Study: NCT03417388
Drug: ACE-I (lisinopril) or ARB (losartan)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension.
Study: NCT02192489
Drug: CC-220 0.3 mg Daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02192489
Drug: CC-220 0.6mg Daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02192489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00203099
Drug: Glatiramer Acetate, N-Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
Study: NCT01755182
Drug: approved pharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03566134
Drug: DA-8010 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive placebo to match DA-8010 orally once a day.
Study: NCT03566134
Drug: DA-8010 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive DA-8010 2.5mg orally once a day.
Study: NCT04198558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03891108
Drug: BMS-986231 Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered BMS-986231 Formulation B as IV infusion for 48 hours.
Study: NCT03891108
Drug: BMS-986231 Formulation D
Normalized name: Rho(D) - Unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered BMS-986231 Formulation D as IV infusion for 48 hours.
Study: NCT01397214
Drug: Megace F
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megace F oral suspension
Study: NCT02919995
Drug: RPL554
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPL554 suspension administered using a nebuliser
Study: NCT02919995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution administered using a nebuliser
Study: NCT01860066
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 via inhaler twice a day
Study: NCT02849899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.
Study: NCT02902289
Drug: Ibuprofen 200 mg/5 mL oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02902289
Drug: MOMENT 200 mg coated tablet
Normalized name: docosahexaenoic acid / phosphatidylserine Oral Capsule [Senior Moment]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02094924
Drug: GSK587323
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of FDC tablet formulation to be taken orally.
Study: NCT00988728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner.
Study: NCT01190462
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02403648
Drug: BIOD-961
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIOD-961 is a lyophilized glucagon formulation.
Study: NCT00531544
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU011248 Expanded Access Protocol for Systemic Therapy
Study: NCT00926718
Drug: remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
Study: NCT00926718
Drug: rocuronium dose + remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
Study: NCT00926718
Drug: rocuronium dose + remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
Study: NCT00926718
Drug: remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
Study: NCT00926718
Drug: rocuronium dose + remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
Study: NCT00926718
Drug: rocuronium dose + remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
Study: NCT02015312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months
Study: NCT00209612
Drug: Campt, Topotesin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day1,15 Y mg/m2, IV (in the vein)
Study: NCT03410693
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
Study: NCT00826202
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg/day
Study: NCT02750917
Drug: Lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
Study: NCT02750917
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
Study: NCT02368860
Drug: oxaliplatin, irinotecan, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
Study: NCT01680042
Drug: Phenytoin paste
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01680042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00953576
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02855788
Drug: Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: metronomic chemotherapy
Study: NCT01340846
Drug: GSK2118436 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2118436 dosed at 150mg twice daily
Study: NCT01340846
Drug: GSK2118436 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2118436 dosed at 75mg twice daily
Study: NCT03714958
Drug: HDM201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT04398927
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Chemotherapy (Oxaliplatin，5-fluorouracil and Irinotecan)
Study: NCT01323101
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
Study: NCT03714672
Drug: Tramadol/Diclofenac 50/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Study: NCT03714672
Drug: Tramadol/Diclofenac 25/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Study: NCT03714672
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Study: NCT03692299
Drug: Saccharomyces Boulardii Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
Study: NCT01399372
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 28-day cycle = 3.5 g/m\^2 intravenously (standard hydration/leucovorin support) on day 2.
Study: NCT02724618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
Study: NCT01421719
Drug: Cystoscopic injection of Botox into the urinary bladder
Normalized name: Sus scrofa urinary bladder preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
Study: NCT02696967
Drug: CLR325
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLR325 Concentrate for solution for infusion
Study: NCT00940953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal spray, one spray per nostril from each of 2 bottles at time 0
Study: NCT02740101
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration of placebo (40 IU)
Study: NCT01956929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 2 weeks, then 4 weeks of washout period, then crossover to metformin.
Study: NCT01471288
Drug: Carum Cravi
Normalized name: Arum palaestinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/kg of body weight
Study: NCT01471288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02547818
Drug: ALZT-OP1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory
Study: NCT02547818
Drug: ALZT-OP1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory
Study: NCT00482053
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/kg will be administered over 2 hours on day -2
Study: NCT00482053
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-medication for rituximab and PBPC infusion. Administered at 650 mg by mouth 1 hour prior to infusion
Study: NCT00482053
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pre-medication for the PBPC infusion. Administered at 100 mg intravenous 1 hour prior to infusion
Study: NCT00225732
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.~Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
Study: NCT01099462
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
Study: NCT01385293
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
Study: NCT02224560
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.
Study: NCT02224560
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study: NCT02198378
Drug: MEOPA and paracetamol
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
Study: NCT00131248
Drug: Metaclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00131248
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03859934
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin treatment
Study: NCT03859934
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: NCT02346058
Drug: Esarin Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01673737
Drug: SAR260301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: film-coated tablets Route of administration: oral
Study: NCT03172910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline for injection
Study: NCT00357006
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mcg adjunctive transdermal estradiol
Study: NCT00357006
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mcg adjunctive transdermal estradiol
Study: NCT05633758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of administration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
Study: NCT01663103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
Study: NCT01917630
Drug: ALV003
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
Study: NCT01917630
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01656408
Drug: MK-8150
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01656408
Drug: Placebo for MK-8150
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00996333
Drug: Gemcitabine, Docetaxel, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles.
Study: NCT01420952
Drug: [11C]LY2428703
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00533936
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00533936
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00533936
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04524351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid oral dosage form, capsule
Study: NCT03446846
Drug: MIN-117 5.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg MIN-117 administered as two MIN-117 2.5 mg capsules as a single dose once daily
Study: NCT03446846
Drug: MIN-117 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg MIN-117 administered as one MIN-117 2.5 mg capsule and one Placebo capsule as a single dose once daily